What Happened

According to Bloomberg reporting surfaced by TNW on August 25, 2026, Oura — the Finnish smart ring maker — is targeting a September US IPO that would raise up to $3bn and value the company at more than $16bn. This represents a sharp step up from the $10.9bn valuation Oura carried after closing its $875mn Series E in September 2025, which included participation from Fidelity, ICONIQ, Whale Rock, and Atreides.

A significant portion of the offering is reportedly expected to come from existing shareholders selling shares rather than from new capital issuance. That detail matters: a large secondary component makes this partly a liquidity event for early backers rather than purely a fundraising round. Those backers have been well served by Oura's trajectory from a niche quantified-self device to a mainstream wellness product.

The company has not publicly confirmed the listing plan. Bloomberg's reporting describes a plan in progress, not a filed prospectus with attached terms. Oura employs over 900 people across offices in San Francisco and Finland, and its latest hardware — the Ring 5 — launched at $399 as the smallest smart ring on the market.

Why It Matters

The jump from $10.9bn to $16bn+ is not incremental. It represents a 47% valuation increase in roughly 12 months, and the entire case for that price rests on one number that Oura has never disclosed publicly: the proportion of revenue that is recurring subscription income versus one-time hardware sales.

Subscription revenue is priced very differently from hardware revenue. A company selling $399 titanium rings is valued on hardware multiples. A company selling $399 rings plus a monthly subscription for AI-driven sleep, recovery, and readiness analytics is valued on software-as-a-service multiples. The gap between those two frameworks is the gap between a $5bn company and a $16bn company.

The S-1 filing, when it becomes public, will reveal three numbers that matter most: total membership count, subscription revenue as a percentage of total revenue, and churn rate. Those figures will benchmark not just Oura but the entire passive health-tracking category — including competitors like Whoop, which reached a $10.1bn valuation and has signalled its own IPO ambitions, and Samsung, which entered the category with the Galaxy Ring.

Who Is Affected

Health-tech and wearable startups building subscription models around continuous biometric data will get their first public look at the unit economics of a ring-form-factor business at scale. Manufacturing rings is inherently constrained — each device is made in a fixed size and cannot be adjusted after purchase, which turns sizing kits and returns into a real cost line rather than a footnote.

AI analytics companies in the wellness and health space should pay attention to Oura's regulatory positioning. The company has been careful to sell wellness insight rather than medical diagnosis. How far it can push toward clinical claims without triggering FDA device regulation is a material question at a $16bn multiple — and it's a template for any AI company generating health recommendations.

Investors and operators evaluating hardware-plus-subscription business models will finally get public data on how ring-scale manufacturing, sizing logistics, and return rates behave as volumes grow. This has been a closely held operational question.

Strategic Implications

For AI startup founders: If you're building AI-driven health analytics on top of wearable data, Oura's S-1 will reveal the subscription economics and churn rates that define what's achievable in passive biometric tracking. Study the filing when it drops — particularly the split between hardware and subscription revenue, and the customer acquisition cost relative to lifetime value.

For developers/operators building with AI APIs: Oura's regulatory boundary between wellness insight and medical diagnosis is a useful case study in how far AI-generated health recommendations can go before triggering device regulation. If you're building health-adjacent AI features, the line Oura draws in its S-1 risk factors section is worth reading carefully.

For non-technical business owners evaluating AI tools: The wearable health data market is consolidating around a few platform players — Oura, Whoop, and Samsung. If you're choosing a health data partner for employee wellness programs or corporate health initiatives, expect these companies to increasingly compete on subscription analytics and AI-driven insights rather than hardware specs. Lock-in will come from the data ecosystem, not the device.

What to Watch Next

The S-1 public filing is the document worth waiting for — it should arrive before September if the listing timeline holds. Watch for three numbers: total members, subscription revenue percentage, and churn. Also monitor whether Oura's patent litigation against Ultrahuman reveals how commoditised the ring hardware category is becoming, since easier-to-build rings threaten the hardware moat that underpins the subscription model.

Frequently Asked Questions

Q: What is Oura's IPO valuation target?

A: According to Bloomberg reporting, Oura is targeting a valuation above $16bn in its September IPO, up from $10.9bn in September 2025. The company aims to raise up to $3bn, with a significant portion expected from existing shareholders selling shares.

Q: How does Oura make money?

A: Oura sells smart rings (the Ring 5 launched at $399) and charges a subscription for AI-driven sleep, recovery, and readiness analytics. The proportion of revenue from subscriptions versus hardware sales has not been publicly disclosed, but it is the key metric that determines whether the $16bn valuation is justified — subscription revenue commands a higher multiple than one-time hardware sales.